- SHINGRIX is a vaccine to help prevent shingles (herpes zoster) and post-herpetic neuralgia in adults 50 years of age and older.
- SHINGRIX is a vaccine to help prevent shingles (herpes zoster) and post-herpetic neuralgia in adults 50 years of age and older.
- SHINGRIX is a vaccine to help prevent shingles (herpes zoster) and post-herpetic neuralgia in adults 50 years of age or older, and adults 18 years of age or older who are at increased risk of herpes zoster.
- SHINGRIX is not used to prevent chickenpox.
- Do not have SHINGRIX if you are allergic (hypersensitive) to any of the ingredients contained in SHINGRIX.
- The most common side effects are headache; stomach and digestive complaints (including nausea, vomiting, diarrhoea and/or stomach pain); muscle pain (myalgia); pain, redness and swelling at the injection site; and tiredness, chills, fever. Most side effects have a duration of 1–3 days.3,5
- Do not have SHINGRIX if you are allergic (hypersensitive) to any of the ingredients contained in SHINGRIX.
- The most common side effects are headache; stomach and digestive complaints (including nausea, vomiting, diarrhoea and/or stomach pain); muscle pain (myalgia); pain, redness and swelling at the injection site; and tiredness, chills, fever. Most side effects have a duration of 1–3 days.3,5
- Do not have SHINGRIX if you are allergic (hypersensitive) to any of the ingredients contained in SHINGRIX.
- The most common side effects are headache; stomach and digestive complaints (including nausea, vomiting, diarrhoea and/or stomach pain); muscle pain (myalgia); pain, redness and swelling at the injection site; and tiredness, chills, fever. Most side effects have a duration of 1–3 days.3,5
- As with all vaccines, SHINGRIX may not fully protect all people who are vaccinated.
SHINGRIX (Recombinant Varicella Zoster Virus Glycoprotein E antigen 50 micrograms (AS01B adjuvanted vaccine)) is indicated for the prevention of herpes zoster (HZ) and post-herpetic neuralgia in adults 50 years of age or older and for adults 18 years of age or older who are at increased risk of herpes zoster. SHINGRIX is a prescription medicine and is fully funded for individuals aged 65 years only. Costs will apply for people who are not 65 years old. A single 0.5 mL dose contains 50 micrograms of gE antigen, adjuvanted with AS01B (composed of the plant extract Quillaja saponaria saponin (QS-21) (50 mcg) and 3-O-desacyl-4’-monophosphoryl lipid A (MPL) from Salmonella minnesota (50 mcg) plus excipients). SHINGRIX should not be administered if you are hypersensitive to any component of this vaccine. SHINGRIX has risks and benefits – ask your doctor if SHINGRIX is right for you. Use strictly as directed. Common side effects: Adults ≥50 years: pain, redness and swelling at the injection site, muscle pain, fatigue, headache, shivering, fever, and gastrointestinal symptoms. This is not a full list. Vaccination with SHINGRIX may not protect all vaccine recipients. If you have side effects, see your doctor, pharmacist or healthcare professional. Additional product information and Consumer Medicine Information (CMI) is available at www.medsafe.govt.nz. Trademarks are owned by or licensed to the GSK group of companies. ©2023 GSK group of companies or its licensor. Marketed by GlaxoSmithKline NZ Ltd, Auckland. Adverse events involving GlaxoSmithKline products should be reported to GSK Medical Information on 0800 808 500. TAPS DA2243ND-PM-NZ-SGX-WCNT-210004. Date of Approval: 02 2023. Date of Expiry: 02 2025.
Adverse events involving GlaxoSmithKline products should be reported to GSK Medical Information on 0800 808 500.
- Centers for Disease Control and Prevention. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2008 May;57(RR-5):1-30.
- Ministry of Health. Immunisation Handbook 2020:538-551. Available at: https://www.health.govt.nz/publication/immunisation-handbook-2020. Accessed December 2022.
- GlaxoSmithKline New Zealand. SHINGRIX Data Sheet. GSK NZ; 2022.
- Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang S-J, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015 May;372(22):2087-96.
- Cunningham H, et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med 2016;375:1019-32.
- Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open. 2014 Jun;4(6):e004833.
- Bharucha T, Ming D, Breuer J. A critical appraisal of ‘Shingrix’, a novel herpes zoster subunit vaccine (HZ/Su or GSK1437173A) for varicella zoster virus. Hum Vaccin Immunother. 2017 Aug;13(8):1789-97.
- Kimberlin OW, Whitlei RJ. Varicella-zoster vaccine for the prevention of herpes zoster. N Engl J Med. 2007 Mar;356(13):1338-43.
- Levin MJ. Immune senescence and vaccines to prevent herpes zoster in older persons. Curr Opin lmmunol. 2012 Aug;24(4):494-500.
- Volpi A. Severe complications of herpes zoster. Herpes. 2007 Sep;14 Suppl 2:35-9.
- Boutry C, et al. The adjuvanted recombinant zoster vaccine confers long-term protection against herpes zoster: interim results of an extension study of the pivotal phase 3 clinical trials ZOE-50 and ZOE-70. Clin Infect Dis 2021 Jul 20;ciab629. doi: 10.1093/cid/ciab629.
- PHARMAC. Shingles vaccine: Shingrix will be the new funded brand. July 2022. Available at: https://pharmac.govt.nz/medicine-funding-and-supply/medicine-notices/shingrix/.
- Strezova A, et al. Long-term protection against Herpes Zoster by the adjuvanted Recombinant Zoster Vaccine: interim efficacy, immunogenicity, and safety results up to 10 years after initial vaccination. Open Forum Infectious Diseases. 2022.
This website is funded and developed by GSK.
This site is intended for NZ residents only.
©2023 GSK or licensor.
Last updated: 06 February 2023